Dysfunctional intracellular trafficking in the pathobiology of pulmonary arterial hypertension

American Journal of Respiratory Cell and Molecular Biology

Volumn 37, Issue 1, 2007, Pages 31-37

  Sehgal, Pravin B ^a   Mukhopadhyay, Somshuvra ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Endothelium; Golgi organelle; Pulmonary hypertension; Vesicular trafficking

Indexed keywords

CYTOKINE RECEPTOR; MONOCROTALINE; MUTANT PROTEIN; N ETHYLMALEIMIDE SENSITIVE FACTOR; NEF PROTEIN; SNARE PROTEIN;

BMPR2 GENE; CELL MIGRATION; CELL PROLIFERATION; ELECTRON MICROSCOPY; GENE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LUNG ENDOTHELIUM; MACACA; MEMBRANE TRANSPORT; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANOXIA; BIOLOGICAL TRANSPORT; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL MEMBRANE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENES, DOMINANT; GOLGI APPARATUS; HUMANS; HYPERTENSION, PULMONARY; MICROSCOPY, ELECTRON; MODELS, BIOLOGICAL; MUTATION; PULMONARY ARTERY;

MACACA; SIMIAE;

EID: 34347235133     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2007-0066TR     Document Type: Review

References (59)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir KE, Eickelberg O, Voelkel NF, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S-24S.
2. Voelkel NF, Cool C, Lee SD, Wright L, Geraci MW, Tuder RM. Primary pulmonary hypertension between inflammation and cancer. Chest 1988;114:225-230.
3. Cool CD, Groshong SD, Oakey J, Voelkel NF. Pulmonary hypertension cellular and molecular mechanisms. Chest 2005;128:565S-571S.
4. Heath D, Smith P, Gosney J, Mulcahy D, Fox K, Yacoub M, Harris P. The pathology of early and late stages of primary pulmonary hypertension. Br Heart J 1987;58:204-213.
5. Smith P, Heath D. Electron microscopy of the plexiform lesion. Thorax 1979;34:177-186.
6. Smith P, Heath D, Yacoub M, Madden B, Caslin A, Gosney J. The ultrastructure of plexogenic pulmonary arteriopathy. J Pathol 1990;160:111-121.
7. Mette SA, Palevsky HI, Pietra GG, Williams TM, Bruder E, Prestipino AJ, Patrick AM, Wirth JA. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis 1992;145:1196-1200.
8. Marecki JC, Cool CD, Parr JE, Beckley VE, Luciw PA, Tarantal AF, Carville A, Shannon RP, Cota-Gomez A, Tuder RM, et al. HIV Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 2006;174:437-445.
9. Burtney A, Rappoport JZ, Bouchet J, Basmaciogullari S, Guatelli J, Simon SM, Benichou S, Benmerah A. Dynamic interaction of HIV-1 Nef with the clathrin-mediated endocytic pathway at the plasma membrane. Traffic 2007;8:61-76.
10. Roeth JF, Williams M, Kasper MR, Filzen TM, Collins KL. HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J Cell Biol 2004;167:903-913.
11. Madrid R, Janvier K, Hitchin D, Day J, Coleman S, Noviello C, Bouchet J, Benmerah A, Guatelli J, Benichou S. Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity. J Biol Chem 2005;280:5032-5044.
12. Merkow L, Kleinerman J. An electron microscopic study of pulmonary vasculitis induced by monocrotaline. Lab Invest 1966;15:547-564.
13. Todorovich-Hunter L, Johnson DJ, Ranger P, Keeley FW, Rabinovitch M. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline. A biochemical and ultrastructural study. Lab Invest 1988;58:184-195.
14. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol Heart Circ Physiol 1988;255:H484-H491.
15. Meyrick B, Reid L. The effect of continued hypoxia on rat pulmonary arterial circulation. Lab Invest 1978;38:188-200.
16. Meyrick B, Reid L. Hypoxia-induced structural changes in the media and adventitia of the rat hilar pulmonary artery and their regression. Am J Pathol 1980;100:151-178.
17. Jaenke RS, Alexander AF. Fine structural alterations of bovine peripheral pulmonary arteries in hypoxia-induced hypertension. Am J Pathol 1973;73:377-398.
18. King AP, Smith P, Heath D. Ultrastructure of rat pulmonary arterioles after neonatal exposure to hypoxia and subsequent relief and treatment with monocrotaline. J Pathol 1995;177:71-81.
19. Wilson DW, Segall H J. Changes in type II cell populations in monocrotaline pneumotoxicity. Am J Pathol 1990;136:1293-1299.
20. Reindel JF, Roth RA. The effects of monocrotaline pyrrole on cultured bovine pulmonary artery endothelial and smooth muscle cells. Am J Pathol 1991;138:707-719.
21. Sztul E, Lupashin V. Role of tethering factors in secretory membrane traffic. Am J Physiol Cell Physiol 2006;290:C11-C26.
22. Stow JL, Manderson AP, Murray RZ. SNAREing immunity: the role of SNAREs in the immune system. Nat Rev Immunol 2006;6:919-929.
23. Jahn R, Scheller RH. SNAREs - engines for membrane fusion. Nat Rev Mol Cell Biol 2006;7:631-643.
24. Bonifacino JS, Glick BS. The mechanism of vesicle budding and fusion. Cell 2004;116:153-166.
25. Matsushita K, Morrell CN, Cambein B, Yang S-X, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O'Rourke B, et al. Nitric oxide regulates exocytosis by 5-nitrosylation of N-ethlymaleimide Sensitive Factor. Cell 2003;115:139-150.
26. Afzelius BA, Schoental R. The ultrastructure of the enlarged hepatocytes induced in rats with a single oral dose of retrorsine, a pyrrolozidine (Senecio) alkaloid. J Ultrastruct Res 1967;20:328-345.
27. Shah M, Patel K, Sehgal PB. Monocrotaline induced endothelial cell megalocytosis involves a Golgi blockade mechanism. Am J Physiol Cell Physiol 2005;288:C850-C862.
28. Mukhopadhyay S, Sehgal PB. Discordant regulatory changes in monocrotaline-induced megalocytosis of lung arterial endothelial and alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006;290:L1216- L1226.
29. Mathew R, Huang J, Shah M, Patel K, Gewitz M, Sehgal PB. Disruption of endothelial-cell caveolin-1α/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 2004;110:1499-1506.
30. Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006;114:912-920.
31. Taraseviciene-Stewart L, Scerbavicius R, Choe H-H, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:L668-L676.
32. Achcar ROD, Demura Y, Rai PR, Taraseviciene-Stewart L, Kasper M, Voelkel NF, Cool CD. Loss of caveolin and heme oxygenase expression in severe pulmonary hypertension. Chest 2006;129:696-705.
33. Mukhopadhyay S, Shah M, Patel K, Sehgal PB. Monocrotaline pyrrole-induced megalocytosis of lung and breast epithelial cells: disruption of plasma membrane and Golgi dynamics and an enhanced unfolded protein response. Toxicol Appl Pharmacol 2006;211:209-220.
34. Mukhopadhyay S, Xu F, Sehgal PB. Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia and senescence: subcellular eNOS localization and live-cell caveolar and cytoplasmic NO imaging studies. Am J Physiol: Heart and Circ Physiol 2006;292:H1373-H1389.
35. Sehgal PB, Mukhopadhyay S, Xu F, Patel K, Shah M. Dysfunction of Golgi tethers, SNAREs and SNAPs in monocrotaline-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2007; 10.1152/ajplung.00463.2006 (In press)
36. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fisher SG, Barst RJ, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-744.
37. Lane KB, Machado RD, Pauciulo MW, Thompson JR, Phillips JA III, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2 encoding a TGF-β receptor, cause familial pulmonary hypertension. Nat Genet 2000;26:81-84.
38. Nishihara A, Watabe T, Imamura T, Miyazono K. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 2002;13:3055-3063.
39. Rudrakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC, Morrell NW. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002;11:1517-1525.
40. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361:1533-1544.
41. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, Morrell NW, Trembath RC, Aldred MA. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005;111:607-613.
42. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-β receptor signaling and turnover. Nat Cell Biol 2003;5:410-421.
43. Hartung A, Bitton-Worms K, Rechtman MM, Wenzel V, Boergerman JH, Hassel S, Henis YI, Knaus P. Different routes of bone morphogenetic protein (BMP) receptor endocytosis influence BMP signaling. Mol Cell Biol 2006;26:7791-7805.
44. Shah M, Patel K, Mukhopadhyay S, Xu F, Guo G, Sehgal PB. Membrane associated STAT3 and PY-STAT3 in the cytoplasm. J Biol Chem 2006;281:7302-7308.
45. Morrell NW. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? Proc Am Thorac Soc 2006;3:680-686.
46. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-221.
47. Tyler RC, Muramatsu M, Abman SH, Stelzer TJ, Rodman DM, Bloch KD, McMurtry IF. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol 1999;276:L297-L303.
48. Covers R, Oess S. To NO or not to NO: 'where?' is the question. Histol Histopathol 2005;19:585-605.
49. Iwakiri Y, Satoh A, Chatterjee S, Toomre DK, Chalouni CM, Fulton D, Grozmann RJ, Shah VH, Sessa WC. Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc Natl Acad Sci USA 2006;103:19777-19782.
50. Murata T, Sato K, Hori M, Ozaki H, Karaki H. Decreased endothelial nitric-oxide synthase (eNOS) activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Biol Chem 2002;277:44085-44092.
51. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002;161:1357-1369.
52. Charron AJ, Bacallo R, Wandinger-Ness A. ADPKD: a human disease altering Golgi function and basolateral exocytosis in renal epithelia. Traffic 2000;1:675-686.
53. Charron AJ, Nakamura S, Bacallo R, Wandinger-Ness A. Compromised cytoarchitecture and polarized trafficking in autosomal dominant polycystic kidney disease cells. J Cell Biol 2000;149:111-124.
54. Koptides M, Mean R, Demetriou K, Pierides A, Deltas CC. Genetic evidence for a trans-heterozygous model for cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet 2000;9:447-452.
55. Persu A, Duyme M, Pirson Y, Lens XM, Messiaen T, Breuning MH, Chauveau D, Levy M, Grunfeld J-P, Devuyst O. Comparison between siblings and twins supports a role for modifier genes in ADPKD. Kidney Int 2004;66:2132-2136.
56. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bolch KD. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 2004;287:L1241-L1247.
57. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudrakanchana N, Southwood M, James V, Trembath RC, Morrell NW. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006;98:818-827.
58. Song Y, Jones JE, Beppu H, Keaney JF, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005;112:553-562.
59. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 2004;94:1109-1114.